[Year:2020] [Month:September-December] [Volume:24] [Number:3] [Pages:11] [Pages No:104 - 114]
Background: Serum homocysteine levels have been observed to be increased in sickle cell disease (SCD). The biological mechanism of synthesis and regulation of the homocysteine remains unclear. This meta-analysis aims to provide an overview of the serum homocysteine level changes and to discuss its significance in SCD.
Materials and methods: This meta-analysis is to determine serum homocysteine level changes during SCD and was conducted under the PRISMA guidelines. Without language restrictions, the articles were identified through BioMed, Embase, Pub Med® (U.S. National Library of Medicine, USA), and www.Blood Journal.org, PLoS ONE, Web of Science, LILACS (Latin American and Caribbean Health Sciences Literature), ISI Web of Science, Chemical abstract services-(CAS), Europe PMC, Bio sis Previews, Elsevier Properties S.A., USA. The studies have been considered which were published before March 31, 2018.
Results: Thirty comparative studies were identified out of 8,630 articles and included in the meta-analysis. From the final selected articles, the mean, standard deviation, sample size of cases vs controls were showing compared and calculated by the SPSS latest software version-24. From 30, 18 articles were statistically highly significant, and the remaining 12 articles were statistically not significant. The p <0.05 was considered to be statistically significant. The combined estimation of the meta-analysis study is highly significant, since p <0.000000, calculated “t” is 25.07, and degree of freedom is 2,829.
Conclusion: The study concludes that there is an extremely significant difference between mean serum homocysteine levels in cases and healthy controls. So, the serum homocysteine level can be used as a clinical biomarker for the diagnosis of SCD.